LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics

– JIXING to lead development and commercialization of LNZ100 and LNZ101 in Greater China –

– LENZ to receive up to $110 million in upfront and milestone payments, as well as royalty payments based on future net sales –

– RTW to invest $10 million in LENZ Therapeutics –

LENZ Therapeutics (LENZ), a biopharmaceutical company with a lead late clinical-stage program that represents a potential best-in-class therapy for presbyopia, announced that it has entered into an exclusive license agreement with Ji Xing Pharmaceuticals (JIXING) to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment of presbyopia in Greater China. JIXING is a biotechnology company headquartered in Shanghai and backed by RTW Investments, LP (RTW), a leading healthcare investment firm, that is focused on advancing innovative medicines for patients with ophthalmic and cardiovascular diseases in China. In addition, RTW will invest $10 million in LENZ Therapeutics.

Latest Aithority Insights: Uniphore Acquires Colabo to Deliver Knowledge AI and Automation

“In addition, the investment by RTW highlights the promise of LENZ to emerge as a global leader based on its potential best-in-class aceclidine presbyopia eye drop.”

Under the licensing agreement, LENZ will receive $15 million in upfront payments and may receive up to $95 million in additional payments, based on various prescribed development, regulatory and commercial milestones as well as royalty payments based on future net sales.

“We are very excited to work with JIXING and jointly bring our products to one of the largest presbyopia markets in the world,” said Eef Schimmelpennink, CEO of LENZ Therapeutics. “In addition, the investment by RTW highlights the promise of LENZ to emerge as a global leader based on its potential best-in-class aceclidine presbyopia eye drop.”

Browse The Complete News About Aithority: New Survey Finds Visibility the Most Important Cloud Security Factor

“Age-related ophthalmic diseases are a growing challenge in China, with an estimated 440 million patients suffering from presbyopia,” said Joseph Romanelli, CEO of JIXING. “We have built a portfolio in presbyopia and dry eye disease and will continue to expand into more critical ophthalmic disease areas. Our goal is to bring disruptive science to help improve upon the standard of care for patients in China. Today’s collaboration with LENZ is another milestone in fulfilling that commitment.”

“We are excited to work with pioneering companies like LENZ to advance medical innovation in the field of ophthalmology to benefit more patients around the world,” said Roderick Wong, MD, Chairman of JIXING and Managing Partner of RTW. “Through this strategic alliance, we look forward to assisting LENZ in expanding its global reach.”

Read More About Aithority News: Seceon Delivers Unprecedented Growth for Its AI/ML-Based aiSIEM/aiMSSP/aiXDRTM Platforms

 [To share your insights with us, please write to sghosh@martechseries.com]